Insurance underwriting software business Concirrus raised capital to fund product enhancements and entry into new verticals and geographies.

University of Oxford-founded OMass Therapeutics has extended its series A round to progress a pipeline targeting immunological and genetic disorders.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Karolinska Development banked a $32.4m annual profit after the successful IPO of Aprea Therapeutics, amid improvements to its operational finances.

Stanford-StartX Fund contributed to a $12m round for catheter monitor developer CloudCath, whose clinical advisory chairman hails from Stanford University.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The precision cancer therapy developer, based on research from several universities, floated at the top of an upsized range and saw its price continue to rise post-IPO.

Parkwalk Advisors is lining up investment to fund series C rounds for 10 of its portfolio companies, including spinouts of the universities of Oxford and Cambridge.

Braavos Capital has emerged as the largest shareholder in OSI, having picked up stakes from IP Group, Invesco and Woodford Investment Management.

The fourth fund of ULB’s venture unit now stands at $41.2m having extended its investment purview to include spinouts in Quebec.